UA115455C2 - Спосіб одержання сполук для застосування при лікуванні раку - Google Patents

Спосіб одержання сполук для застосування при лікуванні раку

Info

Publication number
UA115455C2
UA115455C2 UAA201504532A UAA201504532A UA115455C2 UA 115455 C2 UA115455 C2 UA 115455C2 UA A201504532 A UAA201504532 A UA A201504532A UA A201504532 A UAA201504532 A UA A201504532A UA 115455 C2 UA115455 C2 UA 115455C2
Authority
UA
Ukraine
Prior art keywords
cancer treatment
preparing compounds
compound
formula
mek
Prior art date
Application number
UAA201504532A
Other languages
English (en)
Ukrainian (uk)
Inventor
Срірам Наганатхан
Натхан Гуз
Меттью Пфайффер
К. Грегорі Сауелл
Трейсі Бостік
Джейсон Ян
Аміт Срівастава
Original Assignee
Екселіксіс, Інк.
Дженентек, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Екселіксіс, Інк., Дженентек, Інк. filed Critical Екселіксіс, Інк.
Publication of UA115455C2 publication Critical patent/UA115455C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA201504532A 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку UA115455C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
UA115455C2 true UA115455C2 (uk) 2017-11-10

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201504532A UA115455C2 (uk) 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку

Country Status (31)

Country Link
US (4) US9771347B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2909188B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP6300042B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102204520B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN104837826B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013328929B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015008113B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2889466C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015000926A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (2) CR20200237A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA030613B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2671502T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP201706690B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1213567A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20180670T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL238116B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN03928A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA38085B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX372708B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY186549A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ706723A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (3) PE20151494A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015500785B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2909188T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA515360271B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201502795VA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2909188T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR201807861T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA115455C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014059422A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201502349B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115455C2 (uk) 2012-10-12 2017-11-10 Екселіксіс, Інк. Спосіб одержання сполук для застосування при лікуванні раку
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
PL3881833T3 (pl) 2015-06-30 2024-05-13 Genentech, Inc. Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
JP2019524820A (ja) 2016-08-12 2019-09-05 ジェネンテック, インコーポレイテッド Mek阻害剤、pd−1軸阻害剤及びvegf阻害剤での組合せ療法
EP3518970A1 (en) 2016-09-29 2019-08-07 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
WO2022192202A1 (en) 2021-03-09 2022-09-15 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US6048885A (en) 1994-04-01 2000-04-11 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
AU756586C (en) * 1997-07-01 2004-01-29 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
DE69826662T2 (de) 1997-07-01 2005-02-17 Warner-Lambert Co. Llc 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
CZ20012139A3 (cs) 1998-12-22 2002-01-16 Warner-Lambert Company Kombinovaná chemoterapie
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
CA2358438A1 (en) 1999-01-07 2000-07-13 David Thomas Dudley Antiviral method using mek inhibitors
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 4′ヘテロアリールジアリールアミン
OA11746A (en) 1999-01-13 2005-05-13 Warner Lambert Co Benzoheterocycles and their use as MEK inhibitors.
CZ20012528A3 (cs) 1999-01-13 2002-06-12 Warner-Lambert Company 1-Heterocyklicky substituované diarylaminy, farmaceutické kompozice na jejich bázi a způsoby léčení
ATE309205T1 (de) 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
IL147618A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
PL352705A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CN1272316C (zh) 1999-09-17 2006-08-30 千禧药品公司 苯甲酰胺和相关的因子Xa抑制剂
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
EA005818B1 (ru) 2000-07-19 2005-06-30 Уорнер-Ламберт Компани Сложные эфиры фениламинобензгидроксамовых кислот
WO2002018319A1 (en) * 2000-08-25 2002-03-07 Warner-Lambert Company Llc Process for making n-aryl-anthranilic acids and their derivatives
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
IL160967A0 (en) 2001-10-31 2004-08-31 Pfizer Prod Inc Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
HUE025767T2 (en) 2002-03-13 2016-05-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
JP4245561B2 (ja) 2002-06-11 2009-03-25 メルク エンド カムパニー インコーポレーテッド (ハロ−ベンゾカルボニル)複素2環p38キナーゼ阻害剤
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド p38阻害剤及びその使用法
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
KR20060021905A (ko) 2003-06-20 2006-03-08 셀테크 알앤디 리미티드 키나아제 억제제로서의 티에노피리돈 유도체
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101099849B1 (ko) 2003-11-19 2011-12-28 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
ATE384058T1 (de) 2003-12-08 2008-02-15 Hoffmann La Roche Thiazolderivate
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
DK1802579T3 (da) * 2004-10-20 2014-01-20 Merck Serono Sa Derivater af 3-arylaminopyridin
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EA032466B1 (ru) 2005-10-07 2019-05-31 Экселиксис, Инк. Способы получения ингибиторов mek
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2101759B1 (en) * 2006-12-14 2018-10-10 Exelixis, Inc. Methods of using mek inhibitors
UA115455C2 (uk) 2012-10-12 2017-11-10 Екселіксіс, Інк. Спосіб одержання сполук для застосування при лікуванні раку
CN105992755B (zh) 2014-02-07 2018-07-13 住友化学株式会社 (r)-1,1,3-三甲基-4-氨基茚满的制造方法
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
US9771347B2 (en) 2017-09-26
EP2909188B1 (en) 2018-03-07
MX2020005533A (es) 2020-10-12
US10793541B2 (en) 2020-10-06
CN108948043A (zh) 2018-12-07
MY186549A (en) 2021-07-26
SA515360271B1 (ar) 2016-05-19
SG11201502795VA (en) 2015-05-28
SI2909188T1 (en) 2018-07-31
BR112015008113B1 (pt) 2022-05-24
GEP201706690B (en) 2017-06-26
ZA201502349B (en) 2019-12-18
NZ706723A (en) 2018-07-27
US20200392104A1 (en) 2020-12-17
JP6300042B2 (ja) 2018-03-28
MX372708B (es) 2020-05-29
CR20200237A (es) 2020-07-26
MX2015004660A (es) 2015-08-07
PE20151494A1 (es) 2015-11-06
CA2889466A1 (en) 2014-04-17
US20170349569A1 (en) 2017-12-07
CN104837826A (zh) 2015-08-12
HRP20180670T1 (hr) 2018-07-13
ES2671502T3 (es) 2018-06-06
HK1213567A1 (zh) 2016-07-08
TR201807861T4 (tr) 2018-06-21
EA030613B1 (ru) 2018-08-31
PL2909188T3 (pl) 2018-08-31
CN108948043B (zh) 2021-05-04
CR20150245A (es) 2015-11-19
US11414396B2 (en) 2022-08-16
PE20200387A1 (es) 2020-02-24
PH12015500785A1 (en) 2015-06-15
PE20191818A1 (es) 2019-12-27
US10239858B2 (en) 2019-03-26
EP2909188A1 (en) 2015-08-26
JP2015533175A (ja) 2015-11-19
KR20150067339A (ko) 2015-06-17
IL238116B (en) 2018-06-28
PH12015500785B1 (en) 2015-06-15
CL2015000926A1 (es) 2015-08-28
WO2014059422A1 (en) 2014-04-17
AU2013328929B2 (en) 2018-01-04
KR102204520B1 (ko) 2021-01-20
CA2889466C (en) 2021-09-14
JP2018052973A (ja) 2018-04-05
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
AU2013328929A1 (en) 2015-04-30
EA201590700A1 (ru) 2015-09-30
CN104837826B (zh) 2018-07-27
HK1213878A1 (en) 2016-07-15
IN2015DN03928A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-10-02
MA38085A1 (fr) 2018-08-31
US20150210668A1 (en) 2015-07-30
BR112015008113A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
UA115455C2 (uk) Спосіб одержання сполук для застосування при лікуванні раку
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX380092B (es) Tratamiento de la osteoartritis.
PH12016500225B1 (en) Novel quinoline-substituted compound
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
TN2014000093A1 (en) Method of treating gastrointestinal stromal tumors
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
PH12016500963A1 (en) Novel dgat2 inhibitors
SG10201900564WA (en) Methods for treating cancer
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
UA114937C2 (uk) Спосіб стимулювання росту рослин із застосуванням карбоксамідних похідних
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
MX357763B (es) Tratamiento para cancer pancreatico.
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
EA201270237A1 (ru) Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
EA201590656A1 (ru) Азаиндолины
EA201490725A1 (ru) Способ лечения мукоэпидермоидной карциномы
NZ715554A (en) Method of treating hypertrophic cardiomyopathy